
Hey there, it’s Vadim 👋
Welcome to a special Monday night edition of the Bio Founder GPS newsletter - courtesy of the recent flu that’s been going around. If you’re reading this, hope you’re staying healthy!
On a more fun note, today I have an exciting update!
If you’ve been following along with the Bio Founder GPS podcast, you know that for my first two conversations, I sat down with investors to pull back the curtain on what they look for, and how they decide what to back (special thanks to Julie Wolf of 2048 Ventures and Jonah Probell of Lexi Ventures).
Today, we’re flipping the script.
For today’s episode, I got to sit down with Laura Hsieh, PhD, Co-Founder and CEO of TippingPoint Biosciences, for the first founder spotlight on the Bio Founder GPS Podcast.
This is a conversation that I’ve been looking forward to for a long time.
As an early mentor to Laura, and an investor in TippingPoint, I’ve had the pleasure of seeing her lead the company from an early-stage UCSF spinout, secure more than $2 million in pre-seed funding, win several pharma-sponsored golden and platinum tickets and recently close an oversubscrubed $4.5 million seed round.
But those milestones only tell part of the story.
Along the way, Laura had to learn how to negotiate a university license, build relationships with pharma, hire a team, raise capital, and continue leading the science - all while operating with the uncertainty and limited runway that come with building an early-stage biotech.
That behind-the-scenes journey is exactly what I wanted to unpack.
In biotech, we often see the headlines: the multimillion-dollar fundraises, the major partnerships, the new programs and milestones.
What we rarely see is what happened behind the scenes - the decisions, tradeoffs, mistakes, relationships, and building blocks that made those outcomes possible.
That’s why I’m especially grateful to Laura for coming on and being so candid about her journey.
She shared not only what worked, but also what she would do differently, what she had to learn along the way, and how her thinking evolved as she grew into the CEO role.
I think that honesty makes this conversation especially valuable for other scientist-founders who are trying to make the same transition, and who may be navigating many of these questions for the first time.
🧭 HERE’S WHAT WE COVERED:
How Laura went from planning an academic career to spinning a company out of UCSF
The shift from perfecting experiments to building toward value inflection points
Why the biotech market has shifted from platform stories toward asset-level proof
The framework that allowed TippingPoint to select its first indication
What Laura’s pre-seed and seed fundraising processes actually looked like
How early-stage founders can start productive conversations with pharma
What Laura would do differently if she were starting again
And much more!
You can watch the full interview, or listen via your podcast platform of choice below.
Listen + subscribe: Spotify / Apple Podcasts / YouTube
And while you cue those up, here are the four lessons from our conversation that I think every scientist-founder should keep in mind 👇
FIRST, A QUICK NOTE
Did you miss the pitch-deck workshop?
Earlier this week, I hosted a live workshop on how to build a pitch deck that helps investors understand not only your science, but why it matters as a business.
More than 70 founders joined live, and honestly, I had a blast. Thank you to everyone who showed up, asked thoughtful questions, and shared what they’re building!
In case you missed it, I’ve made the recording available for the next week:
And for founders who want to go beyond the workshop, I’m very excited to share that enrollment is now open for the Bio Founder GPS Pitch Deck Intensive, beginning June 30.
Over six weeks, we’ll work together to clarify your story, strengthen your deck, and make sure investors can quickly understand the opportunity behind your science.
The founding cohort also includes access to the upcoming Fundraising Intensive, where we’ll build your target investor list and develop a focused outreach strategy for reaching the right funds.
For the founding cohort, the Fundraising Intensive is included at no additional cost.
Enrollment is limited to 12 founders and closes at midnight ET on June 29. Spots are first come, first served.
Now, back to Laura’s story 👇
MAIN TAKEAWAYS
1. Work backwards from your milestones
One of Laura’s observations about the difference between her work as a scientist, and building a company was about how to use her time.
As a scientist in academia, Laura had the time and freedom to explore where the biology led.
Building a company required a very different mindset.
As Laura put it, the question became:
“How can we be most efficient with the budget that we have to do the experiments that are going to give us the biggest value inflection?”
That didn’t necessarily mean lowering the bar for scientific rigor. It meant recognizing that a company doesn’t have infinite time, money, or room for exploration. Every experiment exists within a larger sequence of decisions.
The readout required for an early screen may be different from the readout required for later validation. The fastest system for generating an initial signal may be different from the system eventually needed to convince an investor, a pharma partner, or a regulator.
The CEO’s job is to understand how those pieces connect.
Before committing resources to an experiment, an early-stage team should be able to answer:
What specific question will this experiment resolve?
What decision will the answer allow us to make?
Which company milestone does it support?
Is there a faster or less expensive way to generate a sufficiently reliable answer?
What do we do next if the result is positive? Or negative?
In academia, the goal may be to understand the biology as completely as possible - but in a company, the goal is to generate the right evidence, in the right order, to keep moving the program forward.
In my view, that’s one of the most fundamental shifts from thinking like a scientist to operating like a CEO.
2. A platform is a promise, but an asset is proof
When Laura first began exploring entrepreneurship, biotech investors were highly receptive to platform companies.
The promise was expansive: build a powerful scientific engine, apply it across multiple diseases, and create an entire pipeline of products.
By the time TippingPoint was raising capital, the market winds had changed direction.
Investors had watched platform companies spend millions of dollars developing technologies without demonstrating that those technologies could produce a viable drug.
As Laura observed:
“The best validation of a platform is to show that it’s going to make a product that’s going to work.”
This doesn’t mean platforms no longer matter. A differentiated platform can still create tremendous long-term value. But the platform itself is a hypothesis until it produces something tangible.
For TippingPoint, the long-term vision is to change how drugs are discovered against disease-specific chromatin states.
But the near-term job is more focused: use that platform to produce a therapeutic candidate for a specific disease.
This distinction matters for how founders allocate capital.
The danger is spending years building the platform in the abstract - adding features, assays, datasets, or capabilities without tying those investments to a concrete product.
A stronger strategy is to ask:
What is the simplest credible demonstration of what our platform can do?
Which product would make the platform easiest to believe?
What platform development is essential to producing that product?
What development work can wait until the first asset creates more capital and optionality?
This way, having an asset doesn’t diminish your platform story, but instead provides you with the credibility to tell it.
3. Your first indication should maximize proof, not merely TAM
Choosing a first indication is one of the most consequential decisions for a platform company.
Founders are often pulled toward the largest market. Investors may encourage them to pursue an indication with the biggest theoretical commercial opportunity.
TippingPoint went through that exercise as well. The team considered whether it should move away from DIPG, a devastating pediatric brain cancer, and toward larger, potentially more lucrative indications.
But Laura eventually came back to a more important question:
Where does our platform have the greatest chance of succeeding and proving that it works?
For TippingPoint, the answer continued to be DIPG.
The disease has a clear connection to chromatin dysfunction. Its biology is closely aligned with the specific capabilities of the company’s platform. The unmet need is profound, and the clinical-development path may be achievable with less capital than programs aimed at much larger patient populations.
It will not be the right investment thesis for every fund.
But it may be the indication that provides the clearest proof of what TippingPoint can do.
Laura described building a comparison table across possible indications. For each one, the company considered questions such as:
How strong is the biological rationale?
How specifically does the platform address the disease mechanism?
What would clinical development look like?
How many patients would be required?
How much capital would it take to reach meaningful proof?
What team and capabilities would the program require?
What does success look like for patients, investors, and potential partners?
This is a much stronger framework than asking only which disease has the largest TAM.
4. The fundraising roadmap should exist well in advance
One of the most candid moments in our conversation came when Laura described leaving UCSF and entering the incubator.
She looked at TippingPoint’s bank account and realized that the company literally had just few months of runway.
During much of the pre-seed stage, TippingPoint was operating with approximately four to six months of runway. Funding arrived through a series of rolling SAFEs and convertible notes rather than one clean financing event.
That changed with the seed round. The company secured a lead investor, negotiated a term sheet, completed an equity financing, converted the earlier notes and SAFEs, and formed a more traditional board.
The two processes were fundamentally different, but the larger lesson Laura took from both was that fundraising has to begin far earlier than many scientist-founders expect.
“The CEO’s job is to fundraise for the company.”
That may sound blunt, but it reflects a basic truth: without capital, the science stops.
Laura’s advice is not to accept every check or spend every day pitching. It’s to build the financing logic into the company from the beginning.
A founder should understand:
What the current capital will allow the company to accomplish
Which milestone will support the next financing
What the next two rounds may need to look like
How much capital the program may require before reaching the clinic
Which investor profiles fit that capital requirement and timeline
Where partnerships or non-dilutive funding could change the equation
Looking back, Laura said she would have started fundraising and networking earlier, and spent more time mapping out what future financings would need to look like and what the company would need to accomplish along the way.
The takeaway: don’t wait until the runway is short to think about the next round. Start building the relationships and financing roadmap early, knowing that both will evolve as the company grows.
A FEW MORE FROM LAURA
Talk to “friendly” pharma early
Early pharma conversations can help founders understand what partners will eventually need to see, but the setting matters. Laura found golden-ticket competitions and early-stage programs through groups like Biocom and California Life Sciences especially useful because pharma understood that the company was still early.
By contrast, she found that larger partnering conferences like BIO were not always the best use of time and money for a very early-stage company. Many pharma teams arrive with specific partnering mandates and are primarily looking for more mature assets. At the stage of most pre-seed and seed biotechs, the goal is not necessarily to secure a deal immediately, but to build relationships and gather useful signals early.
Qualify investors as carefully as they qualify you
Laura now pays much closer attention to fund size, check size, investment stage, fund cycle, and expected returns. A fund may like your science but still be structurally wrong for your company. Her advice: ask investors about their fund, speak with founders in their portfolio, and determine early whether the conversation is worth pursuing.
Build your network before you need it
Looking back, Laura wishes she had spent more time during her postdoc meeting founders and building relationships across the biotech ecosystem. Those relationships later became valuable sources of advice on fundraising, hiring, pharma, and operations. It’s much easier to build that network before you urgently need capital, a partner, or a new hire.
Your first hires should give you leverage
At one point, Laura was arriving at the lab around 5 a.m. to run experiments before turning to investor meetings and the rest of the CEO role. It wasn’t sustainable. Her lesson was to find people who understand the vision, complement the founder’s strengths, and can truly own important parts of the work - not simply add another impressive resume to the team.
BROUGHT TO YOU BY ADP
ADP - payroll, benefits, HR, and R&D tax credit support for early-stage biotechs.
Bio Founder GPS readers get founder-friendly pricing:
20–30% lifetime discount on eligible services
Waived sign-on fees
Up to 6 months of free payroll (eligibility-based)
Preferred pricing on HR, compliance, and benefits tools
R&D tax credit setup and support (up to $500K offset against payroll taxes)
THAT’S A WRAP!
A huge thank you to Laura for joining me and being so candid about the journey from postdoc to seed-stage CEO.
There is a tendency to tell founder stories backward.
Once the round has closed and the team is growing, every decision can appear intentional and inevitable.
Laura’s story is more useful because she was open about the reality: learning new jobs in real time, adjusting the company to a changing market, fundraising with limited runway, and gradually developing a much clearer understanding of the milestones, people, and capital required to move forward.
That’s what the transition from scientist to CEO can actually look like.
Resources from the conversation:
A couple of small asks before you go:
If you haven't already, hit follow on Spotify or Apple Podcasts - it genuinely helps us build momentum. And if you watch on YouTube, don't forget to subscribe.
I'd love to hear from you: What’s been your biggest challenge on the path from scientist to CEO? Have you had any recent wins? Reply and let me know, I’d love to hear from you!
See you at our usual time this Sunday!
- Vadim
PS: Do you know a founder, an investor, or a subject matter expert that I should interview? If so, you know what to do 🙂
PPS: If you found this issue useful, the easiest way to support is to forward it to one founder who'd benefit. They can subscribe at biofounder.io